Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense molecules for targeted cancer therapy.

V Wacheck1, U Zangemeister-Wittke

  • 1Department of Clinical Pharmacology, Experimental Oncology/Molecular Pharmacology, Medical University Vienna/AKH, A-1090 Vienna, Austria.

Critical Reviews in Oncology/Hematology
|June 6, 2006
PubMed
Summary

Novel antisense molecules, including antisense oligonucleotides (ASO) and small interfering RNA (siRNA), offer targeted cancer therapy by inhibiting gene expression. Despite past challenges, advancements in targeting and delivery show promise for future clinical efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations.

ESMO open·2025
Same author

Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2009
Same author

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo.

British journal of cancer·2009
Same author

Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound.

European journal of clinical investigation·2009
Same author

Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002.

The British journal of dermatology·2009

Area of Science:

  • Molecular oncology
  • Gene therapy
  • Drug discovery

Background:

  • Traditional chemotherapy lacks specificity, causing toxicity to normal tissues.
  • Understanding cancer genetics reveals specific molecular targets for therapy.
  • Novel biological agents offer improved specificity over cytotoxic drugs.

Purpose of the Study:

  • To review the potential of antisense molecules in cancer treatment.
  • To highlight the mechanisms and advantages of antisense oligonucleotides (ASO) and small interfering RNA (siRNA).
  • To discuss the future prospects of antisense-based cancer therapies.

Main Methods:

  • Review of current literature on antisense technology in oncology.
  • Analysis of gene expression inhibition by ASO and siRNA.

Related Experiment Videos

  • Discussion of challenges and advancements in targeted delivery systems.

    • Main Results:

    • ASO and siRNA specifically target gene expression at the transcript level.
    • These agents are effective against oncogenes, including those with inaccessible protein products.
    • Recent trials faced challenges, but technological improvements are ongoing.

    Conclusions:

    • Antisense molecules represent a promising strategy for targeted cancer therapy.
    • Continued research in target identification, ASO/siRNA technology, and delivery systems is crucial.
    • These advancements offer renewed hope for improved clinical efficacy in cancer treatment.